AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33463426 — intervention group
Group type: COMPARATOR
Intervention: EPN
Number of subjects: 90
Study 33463426 — intervention group
Group type: COMPARATOR
Intervention: TXA
Number of subjects: 90
Study 33153578 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 4050
Study 33153578 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 4050
Study 33153578 — intervention group
Group type: COMPARATOR
Intervention: Optimal medical therapy alone
Number of subjects: 4050
Study 33153578 — intervention group
Group type: EXPERIMENTAL
Intervention: LDL-C <70 mg/dl
Number of subjects: 4050
Study 34767083 — intervention group
Group type: EXPERIMENTAL
Intervention: sEMG-biofeedback rehabilitation
Number of subjects: 17
Study 34767083 — intervention group
Group type: COMPARATOR
Intervention: Control treatment
Number of subjects: 17
Study 34903035 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal denervation (RDN) therapy
Number of subjects: 0
Study 33579247 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronal cleaning of palate and tongue
Number of subjects: 276
Study 33579247 — intervention group
Group type: COMPARATOR
Intervention: Sagittal cleaning of palate and tongue
Number of subjects: 276
Study 33579247 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolerable cleaning depth for palate
Number of subjects: 276
Study 33579247 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolerable cleaning depth for tongue
Number of subjects: 276
Study 33579247 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with male sex and high BMI (overweight/obese)
Number of subjects: 276
Study 33579247 — intervention group
Group type: EXPERIMENTAL
Intervention: Other discomforts reported by participants
Number of subjects: 276
Study 35255859 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard of Care (SOC): nurse-led services for HIV testing plus ART if positive or PrEP for those eligible and negative
Number of subjects: 0
Study 35255859 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexual and Reproductive Health (SRH): Baseline self-collected vaginal and urine samples with study-organized clinic appointments for results, treatment and delivery of HIV testing, ART and PrEP integrated with SRH services
Number of subjects: 0
Study 35255859 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-support: Study referral of participants to a peer navigator to assess their health, social and educational needs and provide risk-informed HIV prevention
Number of subjects: 0
Study 35255859 — intervention group
Group type: EXPERIMENTAL
Intervention: SRH + peer-support: Combination of SRH services and peer navigator support
Number of subjects: 0
Study 35999562 — intervention group
Group type: EXPERIMENTAL
Intervention: Berberine and fenugreek co-supplementation (3 capsules/day of 500 mg: 300 mg of berberine + 200 mg of fenugreek seed powder) for 12 weeks
Number of subjects: 50
Study 34712203 — intervention group
Group type: EXPERIMENTAL
Intervention: Decaffeinated green tea polyphenols (DGTP) 400 mg/day for 12 weeks
Number of subjects: 62
Study 34712203 — intervention group
Group type: COMPARATOR
Intervention: Isodose placebo
Number of subjects: 62
Study 33553662 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention by clinical pharmacists including training on IBS-related knowledge, medication adherence, lifestyle, and diet adjustments.
Number of subjects: 273
Study 33553662 — intervention group
Group type: COMPARATOR
Intervention: Standard medical therapy (nonintervention group).
Number of subjects: 273
Study 33553662 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist intervention (as part of the educational program).
Number of subjects: 273
Study 33037036 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide QWS-AI (2 mg)
Number of subjects: 315
Study 33037036 — intervention group
Group type: COMPARATOR
Intervention: Exenatide two times per day (5 mcg for 4 weeks, followed by 10 mcg for 28 weeks)
Number of subjects: 315
Study 33037036 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide QWS-AI (2 mg) continued for 52 weeks
Number of subjects: 315
Study 35143603 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial alteplase (0.225 mg/kg; maximum dose, 22.5 mg) infused over 15 to 30 minutes
Number of subjects: 121
Study 35143603 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study 35143603 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial alteplase
Number of subjects: 121
Study 33606922 — intervention group
Group type: COMPARATOR
Intervention: GSK3352589 single-dose (2 to 400 mg, including 25 mg food effect arm)
Number of subjects: 68
Study 33606922 — intervention group
Group type: COMPARATOR
Intervention: GSK3352589 repeat-dose (5 to 200 mg, twice daily for 14 days with food)
Number of subjects: 68
Study 33606922 — intervention group
Group type: COMPARATOR
Intervention: GSK3352589 (both single and repeat doses)
Number of subjects: 68
Study 32297043 — intervention group
Group type: EXPERIMENTAL
Intervention: Urea at 40 g/kg DM
Number of subjects: 7
Study 32297043 — intervention group
Group type: EXPERIMENTAL
Intervention: Urea at 60 g/kg DM
Number of subjects: 7
Study 32297043 — intervention group
Group type: EXPERIMENTAL
Intervention: NaOH at 40 g/kg DM
Number of subjects: 7
Study 32297043 — intervention group
Group type: EXPERIMENTAL
Intervention: NaOH at 60 g/kg DM
Number of subjects: 7
Study 32297043 — intervention group
Group type: COMPARATOR
Intervention: Control (no chemical treatment)
Number of subjects: 7
Study 35802515 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise therapy for 3 months
Number of subjects: 148
Study 35802515 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise therapy for 3 months (adherent participants)
Number of subjects: 148
Study 35802515 — intervention group
Group type: COMPARATOR
Intervention: Standard medical care
Number of subjects: 148
Study 33340229 — intervention group
Group type: EXPERIMENTAL
Intervention: Dermabrasion
Number of subjects: 36
Study 33340229 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoblister
Number of subjects: 36
Study 33340229 — intervention group
Group type: EXPERIMENTAL
Intervention: Dermaroller
Number of subjects: 36
Study 32818766 — intervention group
Group type: EXPERIMENTAL
Intervention: S. viridis exposed to NaCl (50 mM) for 12 days
Number of subjects: 2
Study 32818766 — intervention group
Group type: EXPERIMENTAL
Intervention: S. alterniflora exposed to NaCl (up to 550 mM)
Number of subjects: 2
Study 32818766 — intervention group
Group type: EXPERIMENTAL
Intervention: S. viridis under NaCl stress
Number of subjects: 2
Study 32818766 — intervention group
Group type: EXPERIMENTAL
Intervention: S. alterniflora under NaCl stress
Number of subjects: 2
Study 32818766 — intervention group
Group type: EXPERIMENTAL
Intervention: RNA-seq analysis for S. viridis
Number of subjects: 2
Study 32818766 — intervention group
Group type: EXPERIMENTAL
Intervention: RNA-seq analysis for S. alterniflora
Number of subjects: 2
Study 35920102 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgotinib 200 mg (FIL200)
Number of subjects: 147
Study 35920102 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgotinib 100 mg (FIL100)
Number of subjects: 147
Study 35920102 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab (ADA) 40 mg
Number of subjects: 147
Study 35920102 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 147
Study 35920102 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term extension (LTE) filgotinib patients
Number of subjects: 147
Study 35920102 — intervention group
Group type: COMPARATOR
Intervention: Long-term extension (LTE) ADA patients
Number of subjects: 147
Study 34187829 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive airway pressure (PAP) treatment
Number of subjects: 0
Study 34187829 — intervention group
Group type: COMPARATOR
Intervention: Standard care control (no PAP)
Number of subjects: 0
Study 33461636 — intervention group
Group type: EXPERIMENTAL
Intervention: Asenapine 10 mg/day
Number of subjects: 529
Study 33461636 — intervention group
Group type: EXPERIMENTAL
Intervention: Asenapine 20 mg/day
Number of subjects: 529
Study 33461636 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 529
Study 34080890 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline plus Naltrexone (2 mg/day of varenicline plus 50 mg/day of naltrexone)
Number of subjects: 165
Study 34080890 — intervention group
Group type: COMPARATOR
Intervention: Varenicline plus Placebo (2 mg/day of varenicline plus matched placebo)
Number of subjects: 165
Study 32783585 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of lidocaine/prilocaine (EMLA)
Number of subjects: 0
Study 32783585 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 0
Study 32783585 — intervention group
Group type: EXPERIMENTAL
Intervention: Pin electrode stimulation
Number of subjects: 0
Study 32783585 — intervention group
Group type: EXPERIMENTAL
Intervention: Patch electrode stimulation
Number of subjects: 0
Study 35908601 — intervention group
Group type: EXPERIMENTAL
Intervention: Active capacitive-resistive electrical therapy to the lower cervical region (C4-C7), twice weekly for a total of six treatments
Number of subjects: 20
Study 35908601 — intervention group
Group type: COMPARATOR
Intervention: Sham (inactive) treatment
Number of subjects: 20
Study 34161750 — intervention group
Group type: EXPERIMENTAL
Intervention: POD F‐GF group (n = 50)
Number of subjects: 100
Study 34161750 — intervention group
Group type: EXPERIMENTAL
Intervention: POD F group (n = 50)
Number of subjects: 100
Study 35391580 — intervention group
Group type: EXPERIMENTAL
Intervention: Online-supervised corrective exercises
Number of subjects: 36
Study 35391580 — intervention group
Group type: EXPERIMENTAL
Intervention: Workplace corrective exercises
Number of subjects: 36
Study 35391580 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual activities)
Number of subjects: 36
Study 34735441 — intervention group
Group type: EXPERIMENTAL
Intervention: Socio-emotional intervention (including 'Affect Dyad')
Number of subjects: 300
Study 34735441 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention (including 'Breathing Meditation')
Number of subjects: 300
Study 34735441 — intervention group
Group type: COMPARATOR
Intervention: Retest control group
Number of subjects: 300
Study 32224279 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to 5 °C
Number of subjects: 0
Study 32224279 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to 10 °C
Number of subjects: 0
Study 32224279 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to 15 °C
Number of subjects: 0
Study 32224279 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerial exposure
Number of subjects: 0
Study 32224279 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant enzyme activities and T-AOC
Number of subjects: 0
Study 32224279 — intervention group
Group type: EXPERIMENTAL
Intervention: Relative expression levels of Hsp90 and Hsp70 mRNA
Number of subjects: 0
Study 32224279 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune enzyme activities (ACP, AKP, LSZ, T-NOS)
Number of subjects: 0
Study 32224279 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene expression of TLR, Rel, and p105
Number of subjects: 0
Study 33411207 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized version of the inferential reading comprehension intervention
Number of subjects: 66
Study 33411207 — intervention group
Group type: EXPERIMENTAL
Intervention: Teacher-led version of the inferential reading comprehension intervention
Number of subjects: 66
Study 33411207 — intervention group
Group type: COMPARATOR
Intervention: Business-as-usual (BaU) control instruction
Number of subjects: 66
Study 32389738 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical tacalcitol plus 5‐aminolevulinic acid photodynamic therapy (ALA‐PDT)
Number of subjects: 21
Study 32389738 — intervention group
Group type: COMPARATOR
Intervention: 5‐aminolevulinic acid photodynamic therapy (ALA‐PDT) alone
Number of subjects: 21
Study 33798311 — intervention group
Group type: EXPERIMENTAL
Intervention: Cupping treatment combined with antibiotics (cefodizine sodium 80 mg/(kg•d) for 7 days)
Number of subjects: 72
Study 33798311 — intervention group
Group type: COMPARATOR
Intervention: Antibiotics alone (cefodizine sodium 80 mg/(kg•d) for 7 days)
Number of subjects: 72
Study 35248132 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose ticagrelor combined with 100 mg aspirin
Number of subjects: 2090
Study 35248132 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose ticagrelor combined with 100 mg aspirin
Number of subjects: 2090
Study 33555926 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG + FOLFOX
Number of subjects: 567
Study 33555926 — intervention group
Group type: COMPARATOR
Intervention: FOLFOX
Number of subjects: 567
Study 35470972 — intervention group
Group type: EXPERIMENTAL
Intervention: DIET
Number of subjects: 383
Study 35470972 — intervention group
Group type: EXPERIMENTAL
Intervention: DIET+MODPA
Number of subjects: 383
Study 35470972 — intervention group
Group type: EXPERIMENTAL
Intervention: DIET+HIGHPA
Number of subjects: 383
Study 32664052 — intervention group
Group type: EXPERIMENTAL
Intervention: Fex-Can intervention (web-based psycho-educational intervention)
Number of subjects: 0
Study 32664052 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 0
Study 32664052 — intervention group
Group type: EXPERIMENTAL
Intervention: Fex-Can intervention
Number of subjects: 0
Study 34775578 — intervention group
Group type: EXPERIMENTAL
Intervention: AMP5A
Number of subjects: 40
Study 34775578 — intervention group
Group type: COMPARATOR
Intervention: SOC (Control)
Number of subjects: 40
Study 32573831 — intervention group
Group type: EXPERIMENTAL
Intervention: New competing-risks model based on maternal characteristics and medical history.
Number of subjects: 124443
Study 32573831 — intervention group
Group type: COMPARATOR
Intervention: Logistic regression models for different SGA definitions.
Number of subjects: 124443
Study 36257323 — intervention group
Group type: EXPERIMENTAL
Intervention: Pivot
Number of subjects: 188
Study 33542037 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadratus lumborum block III (QLB III)
Number of subjects: 90
Study 33542037 — intervention group
Group type: EXPERIMENTAL
Intervention: Transversalis fascia plane block (TFPB)
Number of subjects: 90
Study 33542037 — intervention group
Group type: COMPARATOR
Intervention: Control (no regional nerve block)
Number of subjects: 90
Study 35686998 — intervention group
Group type: EXPERIMENTAL
Intervention: Occasional cannabis use (1 or 2 times per week) after acute cannabis use
Number of subjects: 85
Study 35686998 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily cannabis use after acute cannabis use
Number of subjects: 85
Study 35686998 — intervention group
Group type: COMPARATOR
Intervention: No cannabis use
Number of subjects: 85
Study 35686998 — intervention group
Group type: EXPERIMENTAL
Intervention: Occasional cannabis use
Number of subjects: 85
Study 34087057 — intervention group
Group type: EXPERIMENTAL
Intervention: Active smoking cessation service by respiratory physicians
Number of subjects: 250
Study 34087057 — intervention group
Group type: COMPARATOR
Intervention: Control group (no active smoking cessation service)
Number of subjects: 250
Study 36282451 — intervention group
Group type: EXPERIMENTAL
Intervention: Empowerment Program (EP), 5 weeks, one session of 20 to 30 minutes each week
Number of subjects: 70
Study 36282451 — intervention group
Group type: EXPERIMENTAL
Intervention: Empowerment Program (EP)
Number of subjects: 70
Study 36282451 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 70
Study 34702439 — intervention group
Group type: EXPERIMENTAL
Intervention: Transtheoretical Model (TTM) intervention, including behavioral processes of change, self-efficacy, and decisional balance
Number of subjects: 414
Study 32560639 — intervention group
Group type: COMPARATOR
Intervention: Intravitreal ranibizumab 0.5 mg alone
Number of subjects: 64
Study 32560639 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab 0.5 mg with macular laser
Number of subjects: 64
Study 33836825 — intervention group
Group type: EXPERIMENTAL
Intervention: Germ Defence intervention via GP practices
Number of subjects: 11100000
Study 33836825 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 11100000
Study 34807763 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (TDF)
Number of subjects: 37
Study 34807763 — intervention group
Group type: COMPARATOR
Intervention: Lamivudine (LAM) for 24 weeks followed by Tenofovir (TDF)
Number of subjects: 37
Study 32048209 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid chromatography-mass spectrometry (LC–MS) and next-generation DNA sequencing
Number of subjects: 49
Study 32048209 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid chromatography-mass spectrometry (LC–MS)
Number of subjects: 49
Study 32048209 — intervention group
Group type: EXPERIMENTAL
Intervention: Next-generation DNA sequencing
Number of subjects: 49
Study 34756350 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (NaHCO3) 300mgkg-1 body weight, supplemented prior to (150mgkg-1) and during (150mgkg-1) a 3-h simulated cycling race.
Number of subjects: 11
Study 34756350 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (NaHCO3)
Number of subjects: 11
Study 34756350 — intervention group
Group type: COMPARATOR
Intervention: NaCl (placebo)
Number of subjects: 11
Study 32955601 — intervention group
Group type: EXPERIMENTAL
Intervention: Erector spinae plane (ESP) block with 20 ml of 0.25% bupivacaine
Number of subjects: 120
Study 32955601 — intervention group
Group type: EXPERIMENTAL
Intervention: Mid-transverse to pleura (MTP) block with 20 ml of 0.25% bupivacaine
Number of subjects: 120
Study 32955601 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 120
Study 35144662 — intervention group
Group type: EXPERIMENTAL
Intervention: Opposing electroacupuncture group
Number of subjects: 100
Study 35144662 — intervention group
Group type: COMPARATOR
Intervention: Sham opposing electroacupuncture group
Number of subjects: 100
Study 34118712 — intervention group
Group type: EXPERIMENTAL
Intervention: StaySafe app (12 weekly sessions)
Number of subjects: 511
Study 34118712 — intervention group
Group type: COMPARATOR
Intervention: Standard practice (SP)
Number of subjects: 511
Study 32654362 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternating cycles of sunitinib and everolimus (12 weeks each)
Number of subjects: 41
Study 32654362 — intervention group
Group type: COMPARATOR
Intervention: Standard sequential treatment of sunitinib followed by everolimus
Number of subjects: 41
Study 36419181 — intervention group
Group type: EXPERIMENTAL
Intervention: IV ketamine (KET) 0.5 mg/kg over 40 min
Number of subjects: 44
Study 36419181 — intervention group
Group type: EXPERIMENTAL
Intervention: IM naltrexone (NTX) 380 mg once
Number of subjects: 44
Study 36419181 — intervention group
Group type: COMPARATOR
Intervention: Linkage alone (LA)
Number of subjects: 44
Study 32267019 — intervention group
Group type: EXPERIMENTAL
Intervention: Media reports not consistent with media recommendations
Number of subjects: 148
Study 32267019 — intervention group
Group type: COMPARATOR
Intervention: Media reports consistent with media recommendations
Number of subjects: 148
Study 32267019 — intervention group
Group type: COMPARATOR
Intervention: Articles about homicide (control group)
Number of subjects: 148
Study 32677699 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine-containing cigarettes in context A
Number of subjects: 40
Study 32677699 — intervention group
Group type: COMPARATOR
Intervention: Placebo cigarettes in context B
Number of subjects: 40
Study 32677699 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine-containing cigarettes in context B
Number of subjects: 40
Study 32677699 — intervention group
Group type: COMPARATOR
Intervention: Placebo cigarettes in context A
Number of subjects: 40
Study 33538413 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis intervention (HI)
Number of subjects: 40
Study 33538413 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-hypnosis practice
Number of subjects: 40
Study 33538413 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control (WC)
Number of subjects: 40
Study 33205924 — intervention group
Group type: EXPERIMENTAL
Intervention: FDS76® dental implant
Number of subjects: 0
Study 32924897 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright white light therapy (BLT)
Number of subjects: 93
Study 32924897 — intervention group
Group type: COMPARATOR
Intervention: Dim red light (DRL)
Number of subjects: 93
Study 33549453 — intervention group
Group type: EXPERIMENTAL
Intervention: Caloric restriction (CR) of −700 kilocalories/day
Number of subjects: 73
Study 33549453 — intervention group
Group type: EXPERIMENTAL
Intervention: Caloric restriction combined with physical activity (CR&PA) of −500 kilocalories/day plus −200 kilocalories/day from PA
Number of subjects: 73
Study 33549453 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving a monthly motivational phone call
Number of subjects: 73
Study 35168637 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual acupuncture
Number of subjects: 252
Study 35168637 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 252
Study 34191423 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise, essential amino acid (AA) ingestion, and tea catechin (TC) ingestion
Number of subjects: 84
Study 34191423 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise and essential AA ingestion
Number of subjects: 84
Study 34191423 — intervention group
Group type: COMPARATOR
Intervention: Exercise
Number of subjects: 84
Study 35226080 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 180
Study 35226080 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study 35226080 — intervention group
Group type: COMPARATOR
Intervention: Standard Care
Number of subjects: 180
Study 33498894 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based intervention (Group 1, n = 36)
Number of subjects: 115
Study 33498894 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual-based intervention (Group 2, n = 30)
Number of subjects: 115
Study 33498894 — intervention group
Group type: EXPERIMENTAL
Intervention: Website-based intervention (Group 3, n = 25)
Number of subjects: 115
Study 32083500 — intervention group
Group type: EXPERIMENTAL
Intervention: Exergaming protocol using Xbox 360 Kinect® with the game Your Shape Fitness Evolved 2012, 2-3 times per week for 20 sessions.
Number of subjects: 38